Emerging drugs for the treatment of acne: a review of phase 2 & 3 trials. (3rd July 2022)

• Record Type: Journal Article
• Authors: Bhatt, Siddharth; Kothari, Rohit; Tripathy, Durga Madhab; Sandhu, Sunmeet; Babaei, Mahsa; Goldust, Mohamad
• Is Part Of: Expert opinion on emerging drugs. Volume 27:Number 3(2022)
• Page Start: 241
• Page End: 261
• Publication Date: 2022-07-03
• Subjects: Acne vulgaris -- phase 2/3 trial -- retinoid -- sebostatic drugs; Drugs -- Research -- Handbooks, manuals, etc; Drugs -- Design -- Periodicals; 615.1072
• DOI: 10.1080/14728214.2022.2110239
• Languages: English
• ISSNs: 1472-8214

Abstract

ABSTRACT: Introduction: Acne vulgaris is one of the commonest dermatoses encountered in a dermatology clinic. Although the inflammatory processes are centered around the pilosebaceous unit, a myriad of external factors that alter the pathogenesis have been hypothesized. Newer therapies are focused on targeting these as possible scaffolds for drug development. Existing topical and oral medications have considerable overlap between pharmacotherapy and cosmeceuticals directed toward acne treatment making new drug development extremely competitive and financially burdening. Teratogenicity associated with retinoids, cutaneous adverse effects of topical anti-acne medications, and lack of long-term remission induction are a few hindrances that have to be tackled by novel therapies. Areas covered: Numerous topical and systemic medications for acne vulgaris are undergoing clinical trials presently. The review has dealt with anti-acne drugs undergoing phase II and III clinical trials with emphasis on the rationale of various combinations in tandem with the complex pathogenesis of the disease. Expert opinion: The current strategies in new drug development target sebocyte function, neo-inflammatory mediators, and methods combatting drug resistance while broadening the anti-microbial spectrum against Cutibacterium acnes . A holistic approach is pivotal to strengthen the management protocol for acne to achieve precision dermatological practice.